Results from the HER2-positive gastrointestinal tumour expansion cohort from a phase Ib study assessing KN026 and KN046 combination therapy showed an ORR of 86% (n = 6/7) in the first-line metastatic GOJ and gastric adenocarcinoma cohort, whereas the ORR in the later line cohort was 44% (n = 8/18) [77]. The gene discussed is ERBB2; the disease is gastric adenocarcinoma.